Leerink Partners Downgrades Mirati Therapeutics (MRTX) to Market Perform

November 7, 2023 6:04 AM EST Send to a Friend
Leerink Partners analyst Andrew Berens downgraded Mirati Therapeutics (NASDAQ: MRTX) from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login